Eli Lilly's obesity pill remains a viable rival to Novo's oral Wegovy despite data that underwhelmed investors

Thread starter U.S. News
Start date Aug 24, 2025

U.S. News

Guest

Aug 24, 2025

Eli Lilly's orforglipron could have a few advantages over a pill from Novo Nordisk, including a lack of dietary restrictions and easier manufacturing.

Continue reading...

You must log in or register to reply here.

Facebook X Bluesky LinkedIn Reddit Pinterest Tumblr WhatsApp Email Link

Thread Information

Title: Eli Lilly's obesity pill remains a viable rival to Novo's oral Wegovy despite data that underwhelmed investors

Prefix: N/A

Forum: USA News

Start date: Aug 24, 2025

Last reply date: Aug 24, 2025

Replies: 0

Thread Tags

Thread statistics

Created: U.S. News, Aug 24, 2025

Replies: 0

Views: 20

About Us

XenTR Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book.

It is a long established fact that a reader will be distracted by the readable content of a page when looking at its layout.

Color picker

Search